ATAC‐seq on iPSC derived astrocytes to assess chromatin accessibility differences between African and European local ancestry. (December 2021)

• Record Type: Journal Article
• Authors: Celis, Katrina; Oron, Oded; Griswold, Anthony J.; Rajabli, Farid; Trittipo, Jack; Feliciano‐Astacio, Briseida E; Cuccaro, Michael L.; Pericak‐Vance, Margaret A.; Dykxhoorn, Derek M.; Young, Juan; Vance, Jeffery M.
• Is Part Of: Alzheimer's & dementia. Volume 17(2021)Supplement 3
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-12
• Subjects: Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.056086
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: Local ancestry (LA) surrounding the APOE4 allele is associated with an increased risk for Alzheimer Disease (AD) in European (EU) LA compared to African (AF) LA. We recently demonstrated that APOE4 has significantly higher expression in astrocytes in brain from EU compared to AF APOE4 LA carriers, but the specific molecular mechanism leading to this difference is not known. We investigated whether evaluating chromatin accessibility and gene expression profiles of inducible pluripotent stem cell (iPSC) derived astrocytes in the LA region in both AF and EU LA could lead us to identify potential regulatory factors affecting chromatin remodeling and expression of APOE . Method: We assayed for Transposase Accessible Chromatin (ATAC‐seq), and RNA‐seq in three iPSC derived astrocytes from two AF LA and one EU LA individuals with AD. We processed the ATAC‐seq data with the ENCODE ATAC‐seq pipeline and called peaks using MACS2. Result: An average of 692 peaks were detected in the LA region with no statistical difference between EU and AF LA. Interestingly, an African APOE4 homozygote LA astrocyte line with high APOE expression had an exclusive ATAC peak at the APOE promoter. Amongst the transcription factors (TFs) suggested to bind this differentially accessible peak in APOE are HNF4A and TEAD4. Both TFs had significantly increased expression in this astrocyte line compared to the other lines. Additionally, differential accessibility in this line include peaks in an intragenic enhancer of PVRL2 and the promoter of CBLC, both shown to be bound by HNF4A and both overexpressed in this cell line and one in the promoter of CYP2S1 with TEAD4 binding, which was also overexpressed. Conclusion: This study is one of the first studies to compare chromatin accessibility in AF and EU ancestries. It also represents initial efforts to investigate potential mechanisms and factors, using iPSC‐derived cell lines, that could contribute to the differential expression we have previously reported in APOE4 between AF and EU LA brains. Our data suggest that elevated astrocytic expression of APOE4 is associated with rs.